Quay is skilled in all aspects of non sterile formulation development. Having investigated the fundamental properties of the drug Quay will prepare a development strategy for the client that ensures that their drug is rapidly and effectively progressed to First in Man (FIM) studies. This can be done by offering solutions as simple as API in capsule, or where needed, providing more complex formulations that offer targeted or phased delivery of the API.
- Tablets and capsules for immediate and controlled release delivery
- Liquid and semi-solid fill in to capsules to improve bioavailability
- Mini tablets and oral liquids for paediatric applications
- Parenteral formulations for early phase tox evaluation
As well as a strong track record in the development of solid and liquid dosage forms, Quay has wide knowledge in the development of topical applications including creams, ointments and more novel delivery mechanisms, such as thermally reversible gels.